Kevin Charles Gorman, CEO of Neurocrine Biosciences (NBIX), has demonstrated a clear selling bias in his insider transactions, with $67 million in total sales compared to $12.1 million in purchases across 34 reported trades. His activity has been exclusively concentrated in NBIX shares, with no trades in other companies. The most significant disposals occurred on August 7, 2025 ($13.4 million) and January 27, 2025 ($21.8 million), supplemented by smaller but consistent sales throughout 2025 and early 2026. Notably, Gorman's recent filings show no buys—only eight sell transactions since January 2025, including three sales on February 13, 2026, totaling over $5 million. The pattern suggests an ongoing reduction in his NBIX position, with sales executed both through open-market transactions (Code S) and planned dispositions (Code F). While some transactions involved derivative securities (Code M), these were typically paired with sales rather than acquisitions. The absence of any purchases since at least 2024 reinforces the directional trend of his trading activity.
AI-assisted summary